|
Patent landscape, scope, and claims: |
United States Drug Patent 5,344,641: Scope, Claims, and Landscape Analysis
Executive Summary
United States Patent 5,344,641, titled "N-substituted 2,3-dihydro-1,4-benzoxazine derivatives," was granted to American Cyanamid Company on September 6, 1994. The patent claims a class of chemical compounds exhibiting therapeutic utility, particularly as calcium channel blockers. The claims are broad, encompassing a specific structural formula with defined variable substituents, and cover pharmaceutical compositions containing these compounds. The patent's expiration date is September 6, 2011. Analysis of the patent landscape reveals a foundational patent for a specific chemical class, with subsequent developments likely focusing on specific compound optimization, therapeutic applications, and formulation improvements.
What is the core innovation claimed by Patent 5,344,641?
The central innovation protected by U.S. Patent 5,344,641 is a specific series of N-substituted 2,3-dihydro-1,4-benzoxazine derivatives. These compounds are characterized by a defined chemical structure with specific positions for substituents. The patent asserts that these compounds possess pharmacologically relevant activity, primarily as calcium channel blockers.
The general chemical structure claimed is represented by Formula I in the patent:
R1
|
C
/ \
O N-R2
/ \ /
R3-C=C-R4
\ / \
C=C-R5
|
R6
Key defining features of Formula I and its accompanying definitions are:
- Aryl or heteroaryl group: The 1,4-benzoxazine core is substituted at specific positions.
- Substituents R1, R2, R3, R4, R5, R6: These represent various functional groups, including alkyl, alkoxy, halo, amino, nitro, cyano, and others. The specific nature and position of these substituents are crucial for defining the scope of the claims.
- Therapeutic Utility: The patent explicitly states the compounds are useful for treating conditions mediated by calcium channel blockade, such as hypertension, angina pectoris, and cardiac arrhythmias.
What are the specific claims within Patent 5,344,641?
Patent 5,344,641 contains multiple claims that define the protected intellectual property. These claims are sequential, with later claims often depending on or narrowing the scope of earlier claims.
Claim 1 (Independent Claim): This is the broadest claim and defines the core chemical entity. It claims:
"A compound of the formula:
R1
|
C
/ \
O N-R2
/ \ /
R3-C=C-R4
\ / \
C=C-R5
|
R6
wherein R1 is selected from the group consisting of alkyl, haloalkyl, alkoxy, haloalkoxy, cyano, nitro, amino, and amidino;
R2 is selected from the group consisting of alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, and wherein R2 is a group of the formula -CH2-Ar wherein Ar is an aryl or heteroaryl group;
R3 is selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, haloalkoxy, cyano, nitro, amino, and amidino;
R4 is selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, haloalkoxy, cyano, nitro, amino, and amidino;
R5 is selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, haloalkoxy, cyano, nitro, amino, and amidino; and
R6 is selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, haloalkoxy, cyano, nitro, amino, and amidino;
and wherein at least one of R2, R3, R4, R5, and R6 is a group other than hydrogen."
Dependent Claims: The subsequent claims narrow the scope of Claim 1 by specifying particular definitions for the substituents R1 through R6 or by claiming specific sub-classes of compounds within the general formula. Examples include:
- Claims specifying R2 as a particular type of alkyl group.
- Claims defining the nature of the aryl or heteroaryl group when Ar is present.
- Claims limiting the number and type of substituents on the benzoxazine ring.
- Claims directed to pharmaceutical compositions containing a compound of Formula I and a pharmaceutically acceptable carrier.
The precise wording of each dependent claim is critical for understanding the boundaries of protection. For instance, a claim might specify that R2 must be an aryl group containing a specific substituent, thus limiting its scope compared to the broad definition in Claim 1.
What is the expiration date of Patent 5,344,641?
United States Patent 5,344,641 was granted on September 6, 1994. Under standard U.S. patent law at the time of its filing, patents had a term of 17 years from the date of grant. Therefore, the expiration date for U.S. Patent 5,344,641 was September 6, 2011.
What is the therapeutic area and mechanism of action indicated by the patent?
The patent explicitly identifies the therapeutic area as the treatment of conditions mediated by calcium channel blockade. The primary mechanism of action asserted for the claimed compounds is calcium channel blockade.
Specific indications mentioned include:
- Hypertension: By blocking L-type calcium channels in vascular smooth muscle, these compounds would cause vasodilation, lowering blood pressure.
- Angina Pectoris: By reducing myocardial oxygen demand (decreasing heart rate and contractility) and potentially increasing oxygen supply (coronary vasodilation), these compounds would alleviate chest pain associated with insufficient blood flow to the heart.
- Cardiac Arrhythmias: Calcium channel blockers can affect the electrical conduction in the heart, particularly in the sinoatrial (SA) and atrioventricular (AV) nodes, helping to regulate abnormal heart rhythms.
What is the patent landscape surrounding Patent 5,344,641?
The patent landscape for a foundational patent like 5,344,641 typically involves several layers:
1. Prior Art: Before the filing of 5,344,641, there would have been existing patents and scientific literature related to:
- Benzoxazine chemistry.
- Calcium channel blockers as a class of drugs.
- Other chemical entities with similar therapeutic indications.
- The patent would have been examined against this prior art by the U.S. Patent and Trademark Office (USPTO) to establish novelty and non-obviousness.
2. Subsequent Patents Claiming Specific Compounds or Uses:
- Patents claiming specific compounds: Following 5,344,641, researchers and companies would likely have synthesized and tested specific compounds falling within its broad scope. Patents would then be sought to cover these specific, optimized molecules, often with superior potency, selectivity, or pharmacokinetic properties. These patents would depend on or be narrower than 5,344,641.
- Patents claiming new therapeutic uses: Even if a compound was covered by 5,344,641, a patent could be obtained for a novel use of that compound, provided it was not previously known or obvious.
- Patents claiming formulations or manufacturing processes: Innovations in how the compounds are formulated into usable drugs (e.g., extended-release tablets, injectable solutions) or efficient methods for their synthesis would also be patentable.
3. Patents Claiming Related Chemical Scaffolds or Mechanisms:
- Broader patents covering other classes of calcium channel blockers (e.g., dihydropyridines, phenylalkylamines) would co-exist in the landscape, defining alternative approaches to treating the same conditions.
- Patents exploring other mechanisms of action for cardiovascular diseases would also be relevant to the overall therapeutic area.
4. Post-Expiration Landscape:
- Upon the expiration of 5,344,641 in 2011, the chemical compounds and compositions it protected entered the public domain. This means generic manufacturers could produce and market these compounds without infringing the expired patent.
- The market would then be characterized by competition among multiple suppliers of the active pharmaceutical ingredients (APIs) and finished drug products, leading to price reductions.
- However, secondary patents (e.g., on specific formulations, new uses, or improved manufacturing processes) might still be in force, potentially extending market exclusivity for specific branded versions.
Analysis of patent landscape necessitates a deep dive into USPTO and global patent databases, searching for patents citing 5,344,641 as prior art and patents claiming specific compounds within the Formula I structure and their applications. This would involve analyzing patent family relationships, claim scope comparisons, and infringement analyses.
What were the key challenges or considerations for competitors after Patent 5,344,641 was granted?
For competitors seeking to develop or market drugs in the calcium channel blocker space during the term of Patent 5,344,641, several challenges and considerations were paramount:
-
Infringement Risk: The broadest claims of 5,344,641 would pose a significant hurdle. Any compound falling within the defined Formula I, even if developed independently, could be considered infringing. Competitors needed to carefully design around these claims. This typically involved:
- Designing compounds outside the claimed genus: Modifying the core structure or the substituents R1-R6 to fall outside the literal scope of the patent claims.
- Identifying invalidity grounds: Investigating whether the patent was validly granted by the USPTO, looking for prior art that could invalidate one or more claims.
- Seeking licenses: Negotiating with American Cyanamid Company for a license to practice the patented invention.
-
Scope of Dependent Claims: While Claim 1 is broad, dependent claims often narrow the scope to specific, potentially more potent or commercially viable compounds. Competitors had to scrutinize these to understand which specific compounds were most rigorously protected.
-
Patent Term: The patent had a term of 17 years from grant, expiring in 2011. This provided a long period of exclusivity for the patent holder. Competitors had to strategize for market entry either before expiration or after, potentially by developing patentable follow-on innovations.
-
Freedom to Operate (FTO): Competitors needed to conduct thorough FTO analyses. This meant assessing not only 5,344,641 but also any related patents (filed by the same assignee or others) that might cover specific compounds, formulations, methods of use, or manufacturing processes. A clear FTO opinion is essential before investing heavily in R&D and commercialization.
-
Development of Superior Alternatives: A common strategy was to develop compounds with significantly improved properties (e.g., better efficacy, fewer side effects, more convenient dosing) that were either outside the scope of 5,344,641 or could be protected by their own patents.
-
Data Exclusivity and Regulatory Pathways: Even after patent expiration, regulatory exclusivity periods (e.g., Hatch-Waxman Act provisions in the U.S.) could still provide market protection for new chemical entities or new uses, independent of patent status.
-
Evergreening Strategies: The patent holder might have employed strategies to extend market exclusivity beyond the initial patent term. This could include filing new patents on improved formulations, different salt forms, or new medical uses of the compounds. Competitors would need to analyze these secondary patents as well.
What was the market impact and commercial relevance of Patent 5,344,641?
The commercial relevance of U.S. Patent 5,344,641 is tied to its foundational nature for a specific class of calcium channel blockers. While direct sales data linked solely to this patent are not publicly available, its importance can be inferred from the therapeutic class it addresses.
-
Cardiovascular Market Significance: Hypertension and angina are leading causes of morbidity and mortality globally. Calcium channel blockers represent a significant segment of the cardiovascular drug market. Patents protecting novel compounds within this class, therefore, hold substantial commercial potential.
-
Enabling Technology: Patent 5,344,641 provided a degree of exclusivity for American Cyanamid Company (and its successors) to develop and market specific N-substituted 2,3-dihydro-1,4-benzoxazine derivatives. This allowed for investment in clinical trials, manufacturing, and marketing without immediate competition from generic versions of the compounds claimed.
-
R&D Direction: The patent likely guided the R&D efforts of other pharmaceutical companies. Competitors would either attempt to design around its claims, seek licenses, or focus on developing compounds with different mechanisms of action or unrelated chemical structures to treat similar cardiovascular conditions.
-
Generic Entry Post-Expiration: Upon its expiration on September 6, 2011, the patent's claims entered the public domain. This opened the door for generic manufacturers to produce and market unpatented compounds falling within the scope of the expired claims. This would typically lead to increased competition and lower drug prices for these specific compounds.
-
Foundation for Follow-on Innovation: The patent served as a starting point for further research. Subsequent patents likely focused on specific, optimized compounds derived from the general class, potentially with improved pharmacological profiles, or novel formulations and delivery methods. These secondary patents could have extended market exclusivity for particular branded products even after the core patent expired.
To fully assess the market impact, one would need to identify specific drugs that were developed and marketed under the protection of this patent and analyze their sales performance and market share during its enforceability. This often requires access to proprietary company data or specialized market research reports.
Key Takeaways
- U.S. Patent 5,344,641 protects N-substituted 2,3-dihydro-1,4-benzoxazine derivatives with asserted utility as calcium channel blockers for treating hypertension, angina, and arrhythmias.
- The patent's broadest claim, Claim 1, defines a general chemical structure with multiple variable substituents, establishing a broad chemical genus.
- The patent expired on September 6, 2011, marking the end of its period of market exclusivity for the claimed compounds.
- Competitors faced significant challenges related to infringement risk, requiring careful R&D design-arounds, FTO analyses, or licensing negotiations.
- The patent's expiration allowed for generic competition, impacting pricing and market dynamics for the protected chemical class.
- Subsequent patent filings focusing on specific compounds, formulations, or uses likely continued to shape the competitive landscape even after the expiration of Patent 5,344,641.
Frequently Asked Questions
-
Can any company now manufacture compounds claimed by Patent 5,344,641?
Yes, any company can now manufacture compounds that fall strictly within the scope of the expired claims of U.S. Patent 5,344,641, as the patent expired on September 6, 2011. However, they must still ensure they do not infringe on any other active patents, such as those covering specific formulations, manufacturing processes, or new medical uses.
-
What is the difference between the expired Patent 5,344,641 and any subsequent patents on specific drugs within this class?
Patent 5,344,641 claims a broad class of chemical compounds. Subsequent patents often claim specific, highly optimized individual compounds within that class, or particular formulations, methods of use, or manufacturing processes that offer improvements or novel aspects. These later patents can have different expiration dates and provide narrower, but potentially longer-lasting, exclusivity for specific drug products.
-
Did American Cyanamid Company have any blockbuster drugs directly protected by this patent?
Publicly available information does not directly link blockbuster drugs solely and exclusively to Patent 5,344,641. Identifying specific drugs developed under this patent would require detailed analysis of the patent's prosecution history, its cited references, and subsequent patent filings by American Cyanamid Company and its successors, alongside drug approval records.
-
What is the significance of "calcium channel blocker" in the context of this patent?
"Calcium channel blocker" describes the asserted pharmacological mechanism of action for the compounds claimed in the patent. This means the compounds are designed to inhibit the passage of calcium ions into cells, particularly smooth muscle and cardiac muscle cells, which is a mechanism used to treat conditions like high blood pressure and certain heart rhythm disorders.
-
Are there any ongoing legal disputes related to Patent 5,344,641?
Given that Patent 5,344,641 expired in 2011, it is highly unlikely that there are active legal disputes directly challenging its validity or asserting its infringement. Disputes typically occur while a patent is in force. Any ongoing legal actions would likely concern secondary patents related to specific drugs or formulations derived from the technology.
Citations
[1] U.S. Patent 5,344,641. (1994). N-substituted 2,3-dihydro-1,4-benzoxazine derivatives. Issued September 6, 1994. Assignee: American Cyanamid Company.
More… ↓
⤷ Start Trial
|
